A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-11-22
DOI
10.3389/fonc.2018.00539
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant
- (2018) Christine Duncan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients
- (2018) Jatinder K. Lamba et al. LEUKEMIA & LYMPHOMA
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Alzheimer's disease–protective CD33 splice variant mediates adaptive loss of function via diversion to an intracellular pool
- (2017) Shoib S. Siddiqui et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children’s Oncology Group Trial AAML0531
- (2017) Jatinder K. Lamba et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric antigen receptor T-cell therapies for lymphoma
- (2017) Jennifer N. Brudno et al. Nature Reviews Clinical Oncology
- One-domain CD4 Fused to Human Anti-CD16 Antibody Domain Mediates Effective Killing of HIV-1-Infected Cells
- (2017) Wei Li et al. Scientific Reports
- A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33 + Acute Myeloid Leukemia
- (2016) Stacey Zahler et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
- (2016) G. Olombel et al. BLOOD
- An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia
- (2016) Steven R. Leong et al. BLOOD
- Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
- (2016) Kole T. Roybal et al. CELL
- Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells
- (2016) Omkar U. Kawalekar et al. IMMUNITY
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531
- (2016) Jessica A. Pollard et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
- (2016) N Khan et al. LEUKEMIA
- Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
- (2016) David T. Rodgers et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
- (2016) George S. Laszlo et al. Oncotarget
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
- (2014) B. Philip et al. BLOOD
- Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
- (2014) I Pizzitola et al. LEUKEMIA
- Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
- (2013) J. M. Rowe et al. BLOOD
- T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
- (2013) A. Mardiros et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission
- (2013) R. B. Walter et al. BLOOD
- Outcome of older patients with acute myeloid leukemia
- (2013) Mya S. Thein et al. CANCER
- Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy
- (2013) L. Mortland et al. CLINICAL CANCER RESEARCH
- T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
- (2013) M. V. Maus et al. Cancer Immunology Research
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies
- (2012) K. Tamada et al. CLINICAL CANCER RESEARCH
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
- (2011) X. Wang et al. BLOOD
- Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells
- (2011) A. B. Perez-Oliva et al. GLYCOBIOLOGY
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
- (2011) Simona Lapusan et al. INVESTIGATIONAL NEW DRUGS
- Gemtuzumab ozogamicin: is there room for salvage?
- (2010) W. T. Clarke et al. BLOOD
- A large human domain antibody library combining heavy and light chain CDR3 diversity
- (2009) Weizao Chen et al. MOLECULAR IMMUNOLOGY
- Construction of a Large Phage-Displayed Human Antibody Domain Library with a Scaffold Based On a Newly Identified Highly Soluble, Stable Heavy Chain Variable Domain
- (2008) Weizao Chen et al. JOURNAL OF MOLECULAR BIOLOGY
- Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers
- (2008) W. Chen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now